NK105: A New Paclitaxel Nanoparticle for Cancer Treatment
Author Information
Author(s): Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T
Primary Institution: National Cancer Center Research Institute East
Hypothesis
NK105, a micellar nanoparticle formulation, can enhance the antitumour activity of paclitaxel while reducing its neurotoxicity.
Conclusion
NK105 demonstrated significantly improved antitumour activity and reduced neurotoxicity compared to free paclitaxel.
Supporting Evidence
- NK105 showed significantly potent antitumour activity on a human colorectal cancer cell line HT-29 xenograft compared with free PTX.
- The plasma AUC values were approximately 90-fold higher for NK105 than for free PTX.
- Neurotoxicity was significantly weaker with NK105 than with free PTX.
Takeaway
Researchers created a new medicine called NK105 that helps fight cancer better and causes less nerve damage than the usual treatment.
Methodology
The study involved comparing NK105 and free paclitaxel in various cancer cell lines and in mice with human colorectal cancer xenografts, assessing their antitumour activity and neurotoxicity.
Limitations
The study was conducted in animal models, and further clinical trials are needed to confirm the findings in humans.
Participant Demographics
Female BALB/c nu/nu mice and CDF1 mice were used in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website